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Empirical studies suggest that the effect sizes of individual causal risk alleles underlying complex genetic diseases are
small, with most genotype relative risks in the range of 1.1–2.0. Although the increased risk of disease for a carrier is
small for any single locus, knowledge of multiple-risk alleles throughout the genome could allow the identification of
individuals that are at high risk. In this study, we investigate the number and effect size of risk loci that underlie
complex disease constrained by the disease parameters of prevalence and heritability. Then we quantify the value of
prediction of genetic risk to disease using a range of realistic combinations of the number, size, and distribution of
risk effects that underlie complex diseases. We propose an approach to assess the genetic risk of a disease in healthy
individuals, based on dense genome-wide SNP panels. We test this approach using simulation. When the number of
loci contributing to the disease is >50, a large case-control study is needed to identify a set of risk loci for use in
predicting the disease risk of healthy people not included in the case-control study. For diseases controlled by 1000
loci of mean relative risk of only 1.04, a case-control study with 10,000 cases and controls can lead to selection of
∼75 loci that explain >50% of the genetic variance. The 5% of people with the highest predicted risk are three to
seven times more likely to suffer the disease than the population average, depending on heritability and disease
prevalence. Whether an individual with known genetic risk develops the disease depends on known and unknown
environmental factors.
An important benefit from the study of the genetics of human
disease is to predict the risk that individuals may have of suc-
cumbing to a particular disease. Knowledge of this risk can then
be used by the clinician in prevention, diagnosis, prognosis, and
treatment. Currently, clinicians use the family history of a pa-
tient to help assess their risk of a disease with a known genetic
component, with family history formally included in standard
international disease classification systems. With modern mo-
lecular tools, can we improve on the use of family history to
assess genetic risk of disease? For diseases caused by single genes,
the answer is obviously “yes,” but for diseases with complex in-
heritance, the best method to use and the success that might be
expected are unclear. The dominant paradigm in human com-
plex-trait genetics has been to map loci affecting disease risk and
then to identify the causative mutations. Complex traits are
likely to be affected by many genes and mutations, most of
which have a small effect on disease risk. The relative risk of
disease due to one allele is typically of the order of 1.1 to 2.0
(Ioannidis et al. 2006; Bertram et al. 2007), but observed effect
sizes may still represent the upper tail of true effect size. These
findings are consistent with the expectation that quantitative
complex traits in general are affected by a large number of loci. In
species where it is possible to measure the number of loci influ-
encing a trait, around 10–50 loci have been identified, most in-
dividually counting for only a few percent, and together account-
ing for <50% of the genetic variation (Henderson et al. 2004;
Jacobsson et al. 2005; Valdar et al. 2006). The number of risk loci
underlying complex disease and their effect size must be
constrained by the disease parameters of prevalence and herita-
bility, yet, to our knowledge, this relationship has not been ex-
plored.
Identification of causal variants and elucidating disease
pathways through genetic and functional studies is difficult and
time-consuming, particularly if there are many risk loci with
small effects. However, knowledge of all risk loci or knowledge of
causal variants at any one risk locus is not necessary for the
prediction of the risk to disease of individuals in the population.
The recent advances in high-density single-nucleotide polymor-
phism (SNP) technology (Kennedy et al. 2003) have made it pos-
sible to conduct genome-wide association studies (Hirschhorn
and Daly 2005). These studies have been considered as only a first
step to identifying the causal mutations, but the SNPs used in the
association study could be useful to create genome-wide predic-
tors of disease or a “genomic profile” (Khoury et al. 2004) for
disease risk. Janssens et al. (2006) have investigated predictive
testing for complex diseases using multiple genes by simulation.
They examined diseases controlled by up to 400 risk loci, but,
although they considered a range of risk effects and allele fre-
quencies, they did not consider distributions of risk effects that
relate to models of the genetic architecture underlying complex
diseases. More importantly, the model that Janssens et al. used
implicitly assumed that an individual’s true genetic risk is known
without error, so that the correlation between genetic risk and
disease status is simply the square root of the broad-sense heri-
tability on the observed scale. That is, their study does not deal
with the key problem, which is to predict the genetic risk faced
by each individual. Pharoah et al. (2002) quantified the propor-
tion of cases in subsets of the population that are at highest
genetic risk of disease, assuming a polygenic model for which risk
was log-normally distributed, without modeling or estimating
the effects of individual risk loci.
The objective of this study is to quantify the accuracy of risk
prediction from genome-wide association studies and to quantify
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the true disease risk faced by the people predicted to be most at
risk in subsequent samples from the population. To do this we
consider models of the underlying genetic architecture assuming
realistic distributions of the frequencies and effect sizes of risk
loci, constraining the number of risk loci and the mean effect size
to be consistent with disease prevalence and heritability. Using
these models, we estimate the genetic risk of individuals based on
a simulated genome-wide association study (GWAS).
Results
The success of association studies, and also of genomic profil-
ing, depends on the genetic architecture underlying complex
diseases. First, we investigate the relationship between the rela-
tive risk (RR) of genetic loci and the number of loci that con-
tribute to risk of a disease under constraints of known disease
prevalence and heritability. We model the genetic architecture
of complex disease by allowing the effect size and frequency of
risk allele to vary across loci. We go on to use these results to
investigate the possibilities of using multiple risk loci identi-
fied in a GWAS to predict risk of disease in a new population
cohort.
We consider four disease scenarios based on realistic com-
binations of disease prevalence, K = 0.05 or 0.10, and heritabili-
ties of the disease on the observed scale, h2 = 0.1 or 0.2. We con-
sider two distributions of frequency of risk alleles underlying the
disease (Fig. 1): A uniform distribution of allele frequencies that
broadly corresponds to the common-disease common-variant
(CDCV) hypothesis in which the frequency of the increasing risk
allele was simulated as pi ∼ Uniform(0.01,0.99) or a U-shaped dis-
tribution, which broadly corresponds the neutral allele hypoth-
esis (Pritchard 2001).
Number of loci underlying complex diseases
For a given number of disease loci we force the effect sizes to be
consistent with the disease prevalence and heritability param-
eters. The average relative risks for fixed numbers of disease loci
for the four disease scenarios are given in Figure 2. Summary
statistics of the mean and maximum RR, the maximum percent-
age of genetic variance explained by a single locus, and the per-
centage of genetic variance explained by extreme frequency risk
variants describe the properties and differences of the models
(Table 1). For the CDCV model, an average RR of 1.2 corresponds
to 40 or more loci. As expected, fewer loci imply larger average
RR, and the average risk of loci for the approximate neutral
model of evolution is always larger than that for the CDCV
model for the same number of loci. Similarly, the maximum
percentage of genetic variance explained by a single locus is al-
ways larger for the neutral model compared to the CDCV model
when the number of risk loci is the same. However, the relation-
ship between the number of disease loci and their average RR is
broadly similar for the two models. When 1000 risk loci influ-
ence a disease, the maximum contribution to genetic variance of
any single locus is only 3%–4%. As expected, as the sibling risk
increases, the average RR increases if the number of risk loci is
fixed; or, the number of risk loci required increases if the mean
RR is held constant.
We derived an analytic expression for number of loci when
RR and allele frequency are fixed for all loci (Equation 3), which
agrees well with the results of the CDCV model when p = 0.5 and
with the neutral model when allele frequency p = 0.1; e.g., for
K = 0.05 and h2 = 0.2, then for p = 0.5, the number of loci for
fixed relative risks of 1.1, 1.2, 1.4, and 1.6 are 346, 95, 29, and 15,
respectively; and for p = 0.1, the corresponding number of loci
are 889, 227, 59, and 28. Different combinations of K and h2 can
lead to the same sibling (sib) relative risk (Fig. 2); it is this com-
bined parameter that drives the results. Equation 3 can be used to
investigate the impact of K or h2 on the number of loci under-
lying complex diseases (Fig. 3).
Use of GWAS to predict disease risk
Using our models for the genetic architecture of complex dis-
eases, we go on to investigate prediction of genetic risk to disease
from multiple risk loci identified in a GWAS. To do this we simu-
lated a case-control study assuming a single-stage genome-wide
association screen with 500,000 SNPs. The number of disease risk
loci was fixed at 10, 20, 50, 100, 300, or 1000, and allele frequen-
cies were simulated from either the U-shaped (neutral) or uni-
form distribution (CDCV). Table 2 summarizes the number of
loci selected for prediction of genetic risk and the proportion of
variance in log risk that they explain in an independent sample
of people.
For all simulated scenarios, when 10,000 cases and controls
were used, the accuracy with which the genetic risk of disease was
predicted in a new random sample of the population of 1000
individuals was very high (Fig. 4 for CDCV model; results for the
neutral model were similar but less conservative). For example,
for the CDCV model of a disease with prevalence 0.05 and heri-
tability 0.1 caused by 100 risk loci with average RR of 1.15 (Table
1), the accuracy of prediction was 0.97 (Fig. 4). The prediction
equation used 45 loci that explained 94% of the genetic variance
(Table 2). As the number of risk loci increases from 100 to 300 to
1000, the accuracy remains above 0.70, even though the average
genotype relative risk falls below 1.1 (Fig. 4). The number of loci
included in the prediction profile continues to increase as the
total number of risk loci increases (Table 1), although the per-
centage of genetic variation they explain decreases. Even when
only 1000 cases and controls were used, the accuracy of predic-
tion was high (>0.7) unless the number of disease loci was >50,
corresponding to average RR of disease alleles of <1.2. A GWAS of
this size does not have sufficient power to detect risk loci with
low average RR, and hence the number of loci selected for inclu-
Figure 1. Distribution of allele frequencies under the neutral and
common-disease common-variant (CDCV) models from 10,000 simu-
lated loci.
Prediction of individual disease risk
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sion in the prediction profiles and the percentage of genetic
variation they explain drops off (Table 1). The results are broadly
similar for the CDCV and neutral disease models. The power of
our approach is demonstrated in Figure 5 for CDCV, where the
true RR of disease for the individuals with the highest 5% of
predicted risk in a new sample is shown relative to the mean
empirical population risk (∼0.05 or 0.10 when population preva-
lence K = 0.05 or 0.10, respectively). Case-control samples of
1000 can generate SNP risk profile sets that identify individuals
who have risk of disease three times higher than the population
average when the number of disease loci is <50.When the case-
control sample is 10,000, individuals in the population that have
a three to seven times increased risk of disease can be identified
even when the number of disease loci is very large (1000). That is,
individuals that have an absolute risk of disease of 15%–70% can
be identified. The results are broadly similar for the CDCV and
neutral disease models; the accuracy was slightly higher under
the neutral model except when the number of risk loci was small.
The high accuracy of prediction is not explained by the presence
of a few loci of very large effect (the mean maxima RR are listed
in Table 1). Under the null hypothesis, one marker is expected,
by chance, to have a test statistic that exceeds the threshold of
22.59. Selection of, on average, one false positive was confirmed
in the simulations. When the number of true risk loci is small,
their mean RR is higher for the same heritability of the disease, so
that even with only 1000 cases and 1000
controls in the association study, most
of the true disease loci are selected.
When the number of risk loci is high,
the mean RR is low, but the distribution
of RR means that almost all the genetic
variance is explained by a fraction of the
risk loci.
Discussion
We have quantified the number of dis-
ease loci underlying common disease us-
ing realistic parameters and have shown
that results from GWAS can be used to
identify healthy individuals in the popu-
lation who are at a substantially in-
creased risk of developing disease, even
when individual risk loci confer small
relative risks. From our model we first
determined the relationship between
the number of susceptibility loci under-
lying a complex disease and their aver-
age RR, given the allele frequency distri-
bution of risk alleles, the population
prevalence, and the heritability. Our re-
sults are robust to the distribution of risk
allele frequencies assumed (approximat-
ing the CDCV or neutral model). We as-
sume additive gene action on the log risk
scale (multiplicative gene action on the
risk scale), that loci act independently
and that there is no linkage disequilib-
rium between disease predisposition
loci. Four disease scenarios were consid-
ered that are representative of complex
diseases, such as major depression, hy-
pertension, heart disease, or type II diabetes; a population preva-
lence of 5% or 10%; and heritability on the observed disease scale
of 10% or 20%. These choices of parameters translate to diseases
with relative risks for full-sibs of affected probands (s) ranging
from 1.45 to 2.90. The analytic formula for the number of loci,
assuming all loci to have the same effect and the same allele
frequency, was found to be a robust predictor of the number of
loci estimated by simulation when frequencies and effect sizes
were sampled from a distribution; using Equation 3 with allele
frequency, p = 0.5 or 0.1, gave results that agreed well with the
CDCV or neutral model simulation, respectively. The analytic
result is a convenient way to investigate the impact of disease
prevalence and heritability on the number of loci underlying
disease (Fig. 3). The number of disease risk loci that underlie
complex disease have previously been investigated (Yang et al.
2005) based on an epidemiological parameterization using popu-
lation-attributable fractions (rather than heritability), assuming
equal frequencies and effects of risk loci. In Appendix A we derive
closed-form solutions for the number of disease risk loci based on
their parameterization.
In addition to the simulations reported here, we also simu-
lated a disease with prevalence K = 0.01 and heritability h2 = 0.05
(corresponding to a sibling RR of 3.48) and found results similar
to those for a disease with similar relative sibling RR, e.g.,
K = 0.05, h2 = 0.25. As with the other disease scenarios, we were
Figure 2. Relationship between the number of susceptibility or risk loci and their average relative risk
(RR) for common disease; K is the population prevalence of the disease; h2 is the heritability on the
observed scale; s is the RR for full-siblings based on the heritability and prevalence parameters.
Distribution of effects of risk loci under neutral (A) and CDCV (B) models. The mean RR are the mean
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able to identify individuals who had an increased risk of disease
that was three to five times higher than average, but when preva-
lence is so low this still translates to a small absolute risk of
disease, and so genomic profiling may be less useful for rare dis-
eases. However, we note that low-prevalence diseases often show
evidence for nonadditive genetic effects (monozygotic twin con-
cordance rates several fold higher than dizygotic twin concor-
dance rates, e.g., schizophrenia, type 1 diabetes, Crohn’s disease),
implying that models that include nonadditive genetic effects
may be more relevant to these disorders.
Our results show that, even for diseases controlled by 1000
loci with mean RR of only 1.04, a case-control study with 10,000
cases and controls can lead to selection of ∼75 loci that explain
>50% of the genetic variance, resulting in accuracy of risk pre-
diction of >0.75. Prediction of increased risk to disease will be
more successful for diseases with a high sibling risk. However, for
diseases of low prevalence, the increased RR may translate into
only a small absolute risk to disease. In contrast, for a disease of
higher prevalence, the increase in RR for the top proportion of a
population based on estimated risk may be small but may trans-
late into a substantial absolute risk of disease. Examination of the
true RR of disease for the individuals with the highest 5% of
predicted risk in a new sample relative to the mean empirical
population risk (Fig. 5) shows that, even with a case-control
samples of 1000 for generation of risk profile SNPs, individuals
who have risk of disease three times higher than the population
average can be identified when the number of disease loci is <50.
When the case-control sample is 10,000, individuals in the popu-
lation that have a three to seven times increased risk of disease
can be easily identified even when the number of disease loci is
very large (1000). That is, individuals that have an absolute risk
of disease of 15%–70% can be identified for the prevalences we
have considered. Therefore, following a single large case-control
study and the selection of a small set of SNPs, 100,000s to mil-
lions of individuals could be identified subsequently that are at
substantial increased risk of disease relative to the population
average. Genomic profiles can be viewed as a more accurate pre-
dictor of genetic predisposition than family history. The accuracy
of prediction that we report can be compared with that achieved
from a family history consisting of the disease status of a person’s
mother and father, which is only 0.2–0.3 (√0.5h2; Falconer and
Mackay 1996) for the disease scenarios considered. Whereas all
sibs within a nuclear family will have the same risk based on
family history, a genomic profile will provide individual risk pro-
files utilizing information from inherited risk loci (after all, half
of the genetic variation occurs within families), even if disease
has not been expressed in family members.
The accuracy of prediction ( rggˆ ) is the correlation between
true and predicted genetic risk. This measure is appropriate to
evaluate the utility of genetic profiling because it is the precision
with which we can predict genetic risk. Whether an individual
Figure 3. Relationship between disease prevalence (K) and heritabil-
ity (h2) on number of risk loci contributing to a disease, assuming a fixed
frequency of risk alleles (p) and fixed RR of 1.1 (Equation 3). Based on
results from Figure 1, p = 0.1 approximates to the neutral model and
p = 0.5 approximates to the CDCV model.




Mean RR Max RR PVG1 PVGMAF10 PVGMAF05
CDCV Neutral CDCV Neutral CDCV Neutral CDCV Neutral CDCV Neutral
0.1 0.05 10 1.74 2.07 3.18 4.24 40 45 7.1 24.2 1.9 11.6
50 1.23 1.32 2.01 2.36 18 21 5.9 19.8 1.5 9.0
100 1.15 1.20 1.81 2.01 12 15 5.7 19.2 1.4 8.7
300 1.08 1.10 1.50 1.65 6 8 5.6 18.7 1.4 8.5
1000 1.04 1.05 1.32 1.41 3 4 5.6 18.6 1.4 8.4
0.10 10 1.51 1.73 2.50 3.18 42 46 7.1 24.5 1.9 12.0
50 1.17 1.23 1.76 2.00 19 22 5.9 20.1 1.5 9.2
100 1.11 1.15 1.58 1.73 13 15 5.7 19.2 1.4 8.8
300 1.06 1.08 1.38 1.50 6 8 5.6 18.9 1.4 8.5
1000 1.03 1.04 1.24 1.32 3 4 5.6 18.6 1.4 8.4
0.2 0.05 10 2.03 2.48 4.17 5.45 38 43 6.6 23.8 1.7 11.3
50 1.30 1.41 2.36 2.78 17 20 5.9 19.7 1.5 9.0
100 1.19 1.26 1.97 2.31 12 14 5.7 19.4 1.4 8.8
300 1.10 1.13 1.63 1.82 6 7 5.6 18.8 1.4 8.5
1000 1.05 1.07 1.39 1.51 3 4 5.6 18.6 1.4 8.4
0.10 10 1.74 2.08 3.19 4.11 40 45 7.0 23.9 1.9 11.5
50 1.23 1.31 2.01 2.35 18 21 5.9 19.9 1.5 9.1
100 1.15 1.20 1.80 2.03 12 15 5.7 19.4 1.5 8.8
300 1.08 1.10 1.50 1.68 6 8 5.6 18.9 1.4 8.5
1000 1.04 1.05 1.31 1.39 3 4 5.6 18.7 1.4 8.4
The mean and maximum relative risk (RR) of simulated disease risk loci, percentage of the genetic variance explained by the locus with the largest
individual variance (PVG1), percentage of genetic variance explained by variants with risk minor allele frequency <0.10 (PVGMAF10), and percentage of
genetic variance explained by variants with risk minor allele frequency <0.05 (PVGMAF05) are shown. Mean of 10,000 simulation replicates.
Prediction of individual disease risk
Genome Research 1523
www.genome.org
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genome.cshlp.orgDownloaded from 
with known genetic risk goes on to develop the disease is depen-
dent on known and unknown environmental risk factors. In
practice, genomic profiling would be used in combination with
information of known environmental risk factors (Lyssenko et al.
2005). Without any such information, the accuracy of predicting
disease status is simply rggˆ h. Janssens et al. (2006) suggest that the
ROC (receiver operator curve)-based measure of discriminative
accuracy, the area under the curve (AUC), is an appropriate mea-
sure for evaluating efficiency of genetic profiling, although oth-
ers have disagreed (Lyssenko et al. 2006). A predictor of genetic
risk cannot do better than predict the true genetic risk with an
accuracy of 100%. Yet even in this situation, Janssens et al.
(2006) noted that AUC accuracy is a function of heritability and
disease prevalence. Therefore, AUC seems to us to be a confusing
statistic, and it is preferable to quote the accuracy of the predic-
tion, rggˆ.
To investigate the use of high-density genome-wide genetic
markers for prediction of genetic risk of disease, we have made
some simplifying assumptions. We assumed that the true causal
SNPs were always included in the GWAS, and we ignored linkage
disequilibrium (LD) between simulated SNPs. If all of our SNPs
are viewed as “tag-SNPs” (Carlson et al. 2004) that are selected to
tag ungenotyped SNPs with a minimum r2 value of 0.8, then
500,000 carefully selected SNPs will capture nearly all of the com-
mon variation in the genome (Barrett and Cardon 2006). In this
case, our accuracy of prediction may be less than that calculated
in our study, by a factor of at most r = 0.9. We chose a simple
method to select SNPs based upon a predetermined number of
false positives (∼1 out of 500,000) and a stringent type I error rate
of 2 106. More complex methods could be used to select
SNPs and to ensure unbiased estimates of effect size of variants
contributing to the genomic profile (e.g., Meuwissen et al. 2001;
Tibshirani et al. 2002; Storey and Tibshirani 2003; Zollner and
Pritchard 2007), and such methods could be adapted to account
for LD between the SNPs. However, our demonstration that a
simple method performs adequately suggests that improvements
from applying other SNP selection algorithms are not going to
change the overall conclusions. We also ignored dominance and
epistasis in the genetic model for disease because there is over-
whelming evidence that most genetic variation is additive by
nature, even when genes interact at a mechanistic level (Barton
and Keightley 2002). Evidence that highly associated variants act
additively (with disease risks of associated variants combining
multiplicatively) in the same way as we have modeled has been
shown recently for age-related macular degeneration (Maller et
al. 2006). Nonetheless, evidence from experimental organisms
Figure 4. Accuracy of risk prediction of disease risk in a population
sample using a set of predictive SNPs selected after a genome-wide as-
sociation study of N each of cases and controls. A CDCV disease model is
assumed with population prevalence (K) and heritability (h2) of the dis-
ease. Results for the neutral model were similar. Mean of 100 simulation
replicates. The legend lists the data series in their order at 1000 risk loci.




1000 cases and controls 10,000 cases and controls
No. of selected loci PVE No. of selected loci PVE
CDCV Neutral CDCV Neutral CDCV Neutral CDCV Neutral
0.1 0.05 10 6.1 5.6 94 92 9.6 8.1 100 100
50 9.8 8.6 67 69 30.4 28.2 97 97
100 8.8 8.3 45 5 44.5 42.0 94 94
300 4.7 5.5 15 2 71.0 63.4 80 82
1000 1.9 2.0 2 4 74.2 73.4 50 56
0.10 10 5.5 4.9 89 89 8.9 8.6 100 99
50 6.7 6.3 54 59 26.0 24.2 96 96
100 5.4 5.4 33 41 37.4 33.4 90 90
300 2.7 3.2 8 14 52.8 47.8 72 75
1000 1.1 1.5 1 2 45.5 47.1 38 45
0.2 0.05 10 7.3 6.6 97 94 9.9 9.5 100 100
50 13.0 11.0 75 76 33.3 30.8 98 98
100 12.8 11.9 56 60 52.7 47.2 96 96
300 8.5 9.4 24 31 89.7 79.7 86 87
1000 3.1 4.0 4 7 110.0 104.0 60 65
0.10 10 6.7 5.8 94 93 9.4 8.9 100 100
50 9.8 9.3 67 70 30.4 41.7 98 97
100 9.1 9.0 46 53 45.4 65.1 94 94
300 4.9 6.1 15 23 72.8 75.3 81 83
1000 2.0 2.3 2 4 78.6 75.3 51 57
The number of loci selected from the genome-wide association study to predict risk in a new population sample of individuals and the percentage of
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suggests that gene gene interactions are likely to be important
in some complex traits (Mackay 2004). We also did not consider
gene environment interactions; just as knowledge of environ-
mental risk factors can be included into association studies, so
can they be included in prediction of genetic risk to disease.
Although many specific models could be defined, we believe the
results given here will apply in general terms to a wide range of
model assumptions. The high accuracy of prediction of risk that
we achieve is partly attributable to the large case-control study
samples that we have assumed, but large sample sizes are recog-
nized as necessary for GWAS, and samples of >1000 cases and
1000 controls are already being genotyped (http://www.ncbi.
nlm.nih.gov/WGA/programs/GAIN/data/; http://www.wtccc.
org.uk/), with even larger samples used for replication studies
(Cox et al. 2007; Sladek et al. 2007).
In the past, lack of replication has been a recurring problem
for genetic association studies, which must, in part at least, be
attributable to lack of power resulting from small sample sizes. In
contrast, GWAS and their subsequent replication studies are
characterized by large study samples. Time will tell if nonrepli-
cation of results and identification of large numbers of false posi-
tives is a characteristic of large-scale GWAS. Nonreplication of
results may remain a problem if there are, as yet, undetermined
methodological problems in genotyping, subtle population
stratification effects, or important gene environment interac-
tion effects. If such problems exist, then our predictions for ge-
netic risk provide an upper bound on the potential for prediction
of genetic risk. GWAS for type 2 diabetes have just been pub-
lished (Saxena et al. 2007; Scott et al. 2007; Zeggini et al. 2007),
and no evidence of confounding from population substructure
and genotyping biases was found. In the Wellcome Trust Case
Control Consortium study (Zeggini et al. 2007) of 459,448 poly-
morphic SNPs genotyped on 1924 cases and 2938 controls, 30
SNPs from nine regions with P < 105 were genotyped on inde-
pendent replication samples. Variants from three of the nine re-
gions survived replication and showed RR of 1.1–1.4. Prevalence
and heritability of type 2 diabetes approximately corresponds our
disease scenario of K = 0.05 and h2 = 0.2. In this situation, we
predict that ∼500 risk loci underlie the disease with mean RR of
1.1 (Fig. 2). In this case, our results show that larger case-control
studies are needed to generate accurate predictions of genetic risk
from a single study (Fig. 4).
We considered two models for the distribution of risk ef-
fects, and we assumed that all genetic variance was attributable
to variants of frequency 0.01 to 0.99. If the true genetic architec-
ture underlying complex diseases means that the majority of ge-
netic variance is explained by variants with minor allele fre-
quency <0.01 (the rare variants model; Pritchard 2001), then
GWAS will fail to detect risk variants that explain much of the
genetic variance because of lack of power and because very rare
variants will not be tagged in a set of 500,000 SNPs. If GWAS fail
to detect risk variants, then prediction of genetic risk will also fail
if it is solely based upon the results from the GWAS. If only part
of the genetic variance is available for detection, h2available, then
accuracy of prediction will decrease by a factor of havailable /h.
Under the neutral model we have simulated ∼50% of the risk
variants have minor allele frequency <0.10 (Fig. 1), and these
variants explain ∼20% of the genetic variance (Table 1). The first
results of the Wellcome Trust Case Control Consortium (2007)
have been published and have shown that the number of risk loci
that they detect, the proportion of variance they explain, and the
conclusion that larger sample sizes are needed are all in line with
the models we have used.
Our simulation model allows direct investigation of the
most important underlying factors that drive whether genomic
profiling is feasible. Our results provide a foundation stone upon
which further layers of complexity can be added, but such an
exercise is only worthwhile if the foundation is sufficiently solid.
All the caveats that apply to GWAS and their replication apply to
the derivation of a SNP set that together predict genetic risk and
its validation, ensuring that discovery, validation, and applica-
tion populations are the same.
The need for new methodology for prediction of genetic risk
has been recognized (Collins et al. 2003; Bell 2004; Khoury et al.
2006). Implementation of risk prediction in a clinical context has
serious ethical and social implications (Grosse and Khoury 2006;
Khoury et al. 2006) but has the potential to be of major economic
benefit to population health (Khoury et al. 2006). Our study
shows that prediction of genetic risk is possible, even if there are
hundreds of risk variants each of small effect. Following a large
single-stage GWAS (probably larger than those that are currently
taking place worldwide), a set of SNPs can be selected that can
accurately predict risk of disease in the population. For our pre-
diction, it does not matter (assuming no population stratifica-
tion), as long as the selected SNPs are true positives, whether they
are in linkage disequilibrium with causal variants or causal them-
selves. The value of these predictive SNPs could be reaped long
before the causal mechanism of each contributing variant can be
determined.
Methods
The success of association studies and also of genomic profiling
depends on the genetic architecture underlying complex dis-
eases. Our first aim is to investigate the relationship between the
RR of genetic loci and the number of loci that contribute to risk
of a disease under constraints of known disease prevalence and
heritability. Ultimately, we will model the genetic architecture of
complex disease by allowing the effect size and frequency of risk
allele to vary across loci. However, to give insight into our results
we first derive an analytical expression for the number of loci
that contribute to a disease when the RR () and the allele fre-
Figure 5. Relative risk of disease for the estimated top 5% of individuals
at risk of a new sample of 1000 people following a case-control study with
sample size of N each of cases and controls. A CDCV disease model is
assumed with population prevalence (K) and heritability (h2) of the dis-
ease. Results for the neutral model were similar. Mean of 100 simulation
replicates. The legend lists the data series in their order at 1000 risk loci.
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quency ( p) of the risk alleles are both fixed. We will go on to use
these results to investigate the possibilities of using multiple risk
loci identified in a genome-wide association study to predict risk
of disease in a new population cohort.
We introduce the following notations:
n = number of risk loci
p = frequency risk allele (A)
1 p = frequency of resistant or “wild-type” allele (a)
f0 = probability (affected | wild-type alleles at all loci)
 = relative risk of a risk allele
h2 = heritability of the disease on the observed scale
K = disease prevalence in the population
Number of loci underlying complex disease when frequency
and RR of risk loci are fixed across all loci
To model the underlying genetic control of complex diseases, we
build upon the disease model suggested by Risch (Risch 1990;
Risch and Merikangas 1996). We assume that all genotypes are in
Hardy–Weinberg equilibrium, so that the probabilities of wild-
type, carrier, and homozygous risk genotypes are (1  p)2,
2p(1 p), and p2, respectively. The relative risk of the carrier and
homozygous risk genotypes are assumed to be  and 2, respec-
tively.
Let g = Prob(affected | genotype) = f0x, where x is the total
number of risk alleles across all loci. Since we assume Hardy–
Weinberg equilibrium, x is distributed binomial (2n,p). Given the
population parameters K, p, and h2, we can derive the number of
loci, using the mean and genetic variance of the probability of an
individual being affected.
K = Eg = E f0
x = f0 p + 1 − p
2n
= f0 1 + p − 1
2n (1)
var g = var f0
x = E  f0
x2 − E  f0
22
= f 0
2  1 + p 2 − 12n − 1 + p  − 14n  (2)
For n = 1, the population mean and the genetic variance reduce to
those derived by Risch (1990). The variance of disease prevalence
due to genetic factors is h2K(1 K). Hence, using this expres-




2 + 1 − h2K  − lnK 
ln1 + p 2 − 1 − ln1 + p  − 12. (3)
Number of loci underlying a complex disease when frequency
and RR of risk alleles vary across loci
Next we investigate the number of loci underlying complex dis-
ease of given disease prevalence and heritability when the fre-
quency and RR of risk alleles vary. In this situation there is no
simple analytical method to derive the number of loci (n), and so
we use simulation to determine the mean RR needed to explain
the genetic variance of disease for a given number of loci. For n
loci with allele frequency pi and relative risk parameter i, the
mean and variance of risk (R) are defined as




x = f0E R,










x2 = f 02E R2 − E2R
and CV2 = var(g)/K2 = [E (R2) E2(R )] /E2(R) = E (R2) /E (R) 1],






























then the genetic variance can be calculated conditionally on
the allele frequencies and relative risks, without the need to
sample genotypes for multiple individuals. The approximation
was checked by simulation and was found to work well. Two
distributions of frequency of risk alleles were considered: A uni-
form distribution of allele frequencies that broadly corre-
sponds to the common-disease common-variant (CDCV) hy-
pothesis (Chakravarti 1999; Reich and Lander 2001), in which
the frequency of the increasing risk allele was simulated as
pi ∼ Uniform(0.01,0.99), or a U-shaped distribution that broadly
corresponds the neutral allele hypothesis (Pritchard 2001). In
this case, the density function of p is f (p) = C/[p(1 p)], and the
cumulative density function is F( p) = C ln[(1  p)/p]0
p with
C a constant. To force the cumulative density to 1, we inte-
grate from 0 +  to 1  , with  a small number. Solving
F(1 ) =C ln[(1 p)/p]1 = 1 for C gives C = 0.5/ln[(1 )/].
To simulate an allele frequency from this distribution, we first
draw a random number r ∼ Uniform(0,1), which is a draw from
the cumulative density function F(p), and then solve for p, as
p = 1/{1 + exp[(r 1/2)/C]}. To avoid the simulation of many
allele frequencies that are close to 0 or 1 (with resulting finite
samples that would be monomorphic), we truncated the allele
frequencies at 0.01 and 0.99. To truncate the allele frequencies at pt
and 1pt,  satisfies the relationship, 1/pt 1 = exp[(1/2 )/C],
which can be solved iteratively. For pt = 0.01,  = 0.009183. For
each of the n risk loci, RR was simulated as i = 1 + x (0 1),
with x ∼ Exponential(1). This results in i always being larger
than 1.0, provided that 0, an arbitrary input parameter is >1.0.
The mean of the simulated RR is E () = 0. The i are transformed
so that all the genetic variance is explained by the n loci as
*i = 1 + (i 1)(c0 1)/(0 1), and the adjustment factor c





















ln1 + pi i*
2
− 14 − 	
i=1
n
1 + pi *i − 1
4
= ln1 + h21 − KK.
The mean RR of the n simulated loci is * = ∑ni=1(i*/n), and the *i
are distributed 1 + x(* 1) with x ∼ Exponential(1). This proce-
dure of simulating and transforming relative risks for a fixed
number of loci was implemented to force the set of simulated risk
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prevalence, while keeping the distribution of the effects expo-
nential.
Analysis of case-control data for identification of multiple risk loci
Using our models for the genetic architecture of complex dis-
eases, we go on to investigate prediction of genetic risk to disease
from multiple risk loci identified in a GWAS. To do this we simu-
lated a case-control study assuming a single-stage genome-wide
association screen with 500,000 SNPs. The number of risk loci
was fixed at 10, 20, 50, 100, 300, or 1000, and allele frequencies
were simulated from either the U-shaped (neutral) or uniform
distribution (CDCV). RR of disease loci were simulated from an
exponential distribution, forcing the mean RR to be consistent
with the heritability, population prevalence, and sampled allele
frequencies (as described above). For all other nonsusceptibility
loci, the RR was 1.0 and the allele frequencies were sampled as
described for the risk loci. Using the sampled allele frequencies,
genotypes for each independent locus for each simulated indi-
vidual resulted from two independent draws from a Bernoulli
distribution, which implies Hardy–Weinberg equilibrium. Dis-
ease status was simulated from the genotypes at the true n sus-
ceptibility loci using a Bernoulli distribution with probability





where xij is the number of susceptibility alleles for individual i at
locus j (xij = 0, 1, 2). A case-control study of 1000 or 10,000 cases
and controls was simulated. For each SNP the RR was estimated
by maximum likelihood for a logistic model
logitqi = lnqi1 − qi =  + *i i = 0, 1, 2,
with qi the proportion of cases of genotype i (e.g., aa, Aa, and AA,
for i = 0, 1, 2) who were diseased. The estimate of the RR in the
population (ˆj for locus j) was e
ˆ, with ˆ the estimate of the
regression parameter from the logistic model. Since it is arbitrary
which of the alleles the risk is calculated for, ˆj can be >1 or <1.
A Newton–Raphson algorithm was applied, which converged in
approximately four iterations. In the rare cases where the count
for a genotype was zero, the count was set to 1/2. Loci were
selected for subsequent prediction of risk if the test statistic (a 2
test) for association was above a predetermined threshold of
22.59, which corresponds to an expected number of one false
positive from 500,000 tests and a nominal P-value of 2 106.
Risk prediction in a new sample from the same population
Next we used the SNPs selected from the simulated case-control
study to see how accurately they could predict risk of disease in
a randomly identified population sample. Therefore, we simu-
lated a new independent sample of multilocus genotypes of 1000
individuals using the same properties of the multiple simulated
risk loci. We assumed that disease status was unknown at the
time of predictive testing but that subsequently disease status was
known. Disease status for an individual was simulated condition-
ally on the simulated genotype (G). For each of these individuals,
we knew the true disease probability and estimated disease prob-
ability from the selected SNPs, calculated as,









with n the total number of true risk loci, m the number of se-
lected loci (both true and false), ˆj the estimated RR for locus j
from the case-control study, and xij the number of risk alleles for
individual i at locus j. Note that the estimated risk will deviate
from 1.0 only for the selected loci. Probabilities of disease based
upon observed genotypes at the selected SNP loci were estimated
for all 1000 individuals and were ranked to identify those indi-
viduals that were predicted to be at most risk. The number of
people with disease (simulated from the genotypes at all true
susceptibility loci) was counted among the top 5% of these
ranked probabilities. The ratio of the disease risk among the top
5% relative to the disease risk in the entire sample was calculated.
This is the observed risk of the identified 5% of people that are
most at risk. The accuracy of prediction was quantified by calcu-
lating the correlation between the logarithms of the true and
predicted probability of disease.
Disease parameters
We considered two disease prevalences, K = 0.05 or 0.10, and two
heritabilities on the observed disease scale, h2 = 0.1 or 0.2. A total
of 100 replicates were simulated for each scenario. Note that we
assume additive gene action on the log risk scale (multiplicative
gene action on the risk scale), that loci act independently, and
that there is no linkage disequilibrium between disease predispo-
sition loci. Additive gene action on the log risk scale approxi-
mates to having additive action on an underlying liability scale
(Lynch and Walsh 1998). The heritability and prevalence param-
eters that we used can be interpreted in terms of the relative risk
of a full-sib of an affected individual s ≈ 1 + 0.5h
2(1  K)/K
(Lynch and Walsh 1998). This approximation assumes additivity
on the risk scale, whereas we have additivity on the log risk scale.
For a fixed number of loci, the mean RR is proportional to
h2(1 K)/K, that is, proportional to 1 s.
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Appendix A
Closed solutions for number of risk loci for parameterization
of Yang et al. (2005).
Yang et al. (2005) investigated the number of genes underlying
complex disease by using an epidemiological framework. They
consider an additive-effects (on the risk scale) model for which






j 1 − pg
n−j  jg −  j − 1
where pg is the frequency of risk genotype at a risk locus and g
is the RR of the risk genotype. Using the expected value of the
number of risk genotypes n in the population of pg, this equation
reduces to a closed form of K = f0[1 + npg(g  1)]. Defining
population-attributable fraction (PAF), as PAF = (K  f0)/K, a
closed solution for the number of risk loci is
n =
PAF
1 − PAFpg g − 1
.
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They also consider a multiplicative-effects model (on the risk







j 1 − pg
n−jg
j
which, using the expected value of g
x = [1 + pg(g 1)], with
x = 1 with probability pg and x = 0 with probability (1 pg), re-
duces to a closed form of K = f0[1 + pg(g 1)]




ln1 + pgg − 1
.
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